DrugPatentWatch Database Preview

Details for Patent: 8,231,885

Which drugs does patent 8,231,885 protect, and when does it expire?

Patent 8,231,885 protects MIRVASO and is included in one NDA.

This patent has sixty-four patent family members in twenty-four countries.

Summary for Patent: 8,231,885

Title:	Compounds, formulations, and methods for ameliorating telangiectasis
Abstract:	Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
Inventor(s):	DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee:	Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:	12/544,663
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,231,885
Patent Claim Types: see list of patent claims	Composition; Delivery; Formulation;

Drugs Protected by US Patent 8,231,885

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,231,885

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,426,410	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	➤ Sign Up
8,513,249	Methods and compositions for safe and effective treatment of erythema	➤ Sign Up
8,557,817	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	➤ Sign Up
7,439,241	Compounds, formulations, and methods for treating or preventing rosacea	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,231,885

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Slovenia	2388007	➤ Sign Up
Slovenia	1761266	➤ Sign Up
Slovenia	1631293	➤ Sign Up
Russian Federation	2519676	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,231,885

For more information try a trial or see the plans and pricing